Monitor for future regulatory filings in sub-Saharan Africa and any subsequent purchase orders from Clovis Davis that would indicate revenue generation. Without disclosed minimums or upfront payments, this is a low-conviction catalyst — watch for volume or insider buying as a signal of real commercial traction.
Price Chart
Executive Summary
Evofem entered into a 5-year exclusive distribution agreement with Clovis Davis Pharmaceuticals to commercialize SOLOSEC (secnidazole) for bacterial vaginosis and trichomoniasis in sub-Saharan Africa. Clovis Davis will lead all distribution, promotion, and regulatory filings in the territory, with no upfront or milestone payments disclosed.
Key Facts
- Exclusive 5-year distributorship agreement for SOLOSEC in sub-Saharan Africa, effective April 24, 2026.
- Clovis Davis is responsible for all distribution, marketing, sales, and local regulatory filings.
- No upfront payment, milestone payments, or minimum purchase commitments were disclosed in the filing.
- Clovis Davis must maintain product liability insurance of at least $1M per occurrence and $3M aggregate.
- Evofem's liability is capped at the greater of $500,000 or 12 months of payments under the agreement.
- Evofem trades OTC (EVFM) with 0% analyst bullish consensus (0 Buy, 3 Hold, 3 Sell/Strong Sell).
Financial Impact
No financial terms disclosed — no upfront, milestone, or minimum purchase commitments were filed. The agreement provides potential revenue upside if SOLOSEC gains regulatory approval and market traction in sub-Saharan Africa, but near-term financial impact is unquantifiable.
Risk Factors
- No disclosed minimum purchase commitments — Clovis Davis may not generate meaningful orders.
- Regulatory approvals in each sub-Saharan African country are required and may be delayed or denied.
- Evofem has a history of cash burn and may need additional financing to support manufacturing scale-up.
- Competing products for BV and trichomoniasis exist in the region, including generic metronidazole.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-020417 |
| Exhibit: ex99-1.htm | 0001493152-26-020417 |
| Document: form8-k.htm | 0001493152-26-020417 |
| Document: 0001493152-26-020417-index-headers.html | 0001493152-26-020417 |
| Document: 0001493152-26-020417-index.html | 0001493152-26-020417 |
| Document: 0001493152-26-020417.txt | 0001493152-26-020417 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $0.007000 | awaiting T+20 | — | $0.007000 (+0.00%) |
May 18, 2026 23w ago | 8-K | $0.007000 $0.007000 | · 0.00% | ▼ −1.58% | $0.007000 (+0.00%) |
Apr 30, 2026 25w ago | 8-K | $0.007000 $0.007000 | · 0.00% | ▼ −5.27% | $0.007000 (+0.00%) |
Mar 11, 2026 32w ago | 8-K | $0.009000 $0.009000 | · 0.00% | ▼ −1.98% | $0.007000 (−22.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers